Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

NGS-based Thyroscan Genomic Classifier in the Diagnosis of Thyroid Nodules

12. august 2026 opdateret af: Rigen Biotech

Prospective, Blinded, Multi-center Clincal Study of NGS-based Thyroscan Genomic Classifier in the Diagnosis of Thyroid Nodules

The purpose of this study is to evaluate the accuracy of Thyroscan in the differential diagnosis of benign and malignant thyroid nodules with suspecious ultrasound features

Studieoversigt

Status

Afsluttet

Intervention / Behandling

Detaljeret beskrivelse

The prevalence of thyroid nodules by high-resolution ultrasound can be as high as 20%, though most of them are benign lesions, only about 5%-15% are malignant lesions. Based on 1.4 billion population in China, there are approximately 280 million thyroid nodule carriers, of which approximately 14-42 million are potential patients with thyroid cancer. Now thyroid cancer is the fastest growing cancer and the 4th most common cancer in women in China. Therefore, the key point in the evaluation of thyroid nodules is the differential diagnosis of benign and malignant nodules. At present, the commonly used imaging and cytological diagnostic techniques for thyroid nodules include ultrasound and ultrasound-guided fine needle aspiration biopsy (FNAB), as well as emerging molecular diagnostic techniques.

The purpose of this study is to evaluate the accuracy of Thyroscan in the diagnosis of benign and malignant thyroid nodules with suspecious ultrasound features. For patients who have signed an informed consent, the subjects undergo fine needle aspiration of thyroid nodules classified as C-TIRADS catagories 3 or 4 under the guidance of ultrasound or palpation before receiving surgical treatment. One needle is used to prepare cytological smear, and one needle is preserved and sent to Thyroscan detection.

Undersøgelsestype

Observationel

Tilmelding (Faktiske)

250

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Hangzhou, Kina, 310000
        • Zhejiang Provincial People's Hospital
      • Shanghai, Kina, 200000
        • Shanghai Jiaotong University School of Medicine
      • Tianjin, Kina, 300000
        • Tianjin Medical University Center Hospital
    • Jiangsu
      • Changzhou, Jiangsu, Kina, 213000
        • The First Peple's Hospital of Changzhou

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

Patients that ultrasound scan identified at least one thyroid nodule, which was classified as category 3 and 4 according to the C-TIRADS guideline.

Beskrivelse

Inclusion Criteria:

  1. Patients sign the informed consent form for participating in the reasearch study.
  2. Patient's age is 18 years or older.
  3. Ultrasound showed at least one thyroid nodule, and it was classified as C-TIRADS Category 3/4.
  4. The surgeon has confirmed surgical indication and the subject is willing to undergo the planned surgical intervention at the participating medical institution; or cytology results are benign, and the nodule(s) have remained clinically stable-defined as absence of new high-risk ultrasound features and no significant change in size on serial imaging.
  5. Surgical indications include but are not limited to one of the following conditions: 1) Thyroid nodules are compressed or affect aesthetics; 2) The patient's subjective wishes require surgical removal of the nodules; 3) FNA samples with indeterminate cytology are classified as Bethesda III and IV, requiring diagnostic surgery; 4) After the investigator's assessment, there are other surgical indications.
  6. Preoperative FNAB to obtain sufficient cells.

Exclusion Criteria:

  1. The subject has a history of thyroid tumor.
  2. The subject is not suitable for fine-needle aspiration biopsy and surgical treatment due to other conditions such as comorbid diseases.
  3. Subjects who intend to receive the radiofrequency ablation therapy.
  4. Other conditions determined by the researcher that do not meet the criteria of enrollment.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

Kohorter og interventioner

Gruppe / kohorte
Intervention / Behandling
Ultrasound findings of thyroid nodules classified as type 3 and 4 of C-TIRADS
To evaluate the accuracy of Thyroscan in the differential diagnosis of benign and malignant thyroid nudules with abnormal ultrasound features.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
To evaluation of Thyroscan's performance in diagnosing thyroid nodules
Tidsramme: At the time of postsurgical pathology report, or upon completion of the 12-month follow-up for non-surgical participants.
To explore the sensitivity, specificity, positive predictive value, negative predictive value, consistency and Kappa value of Thyroscan in the diagnosis of thyroid nodules with ultrasound features classified as C-TIRADS category 3/4.
At the time of postsurgical pathology report, or upon completion of the 12-month follow-up for non-surgical participants.

Sekundære resultatmål

Resultatmål
Tidsramme
To compared with cytopathology and Thyroscan in diagnosing thyroid nodules.
Tidsramme: At the time of postsurgical pathology report, or upon completion of the 12-month follow-up for non-surgical participants.
At the time of postsurgical pathology report, or upon completion of the 12-month follow-up for non-surgical participants.

Andre resultatmål

Resultatmål
Tidsramme
To reveals the correlation between molecular landscape and clinical-pathological characteristics of thyroid nodules.
Tidsramme: At the time of postsurgical pathology report, or upon completion of the 12-month follow-up for non-surgical participants.
At the time of postsurgical pathology report, or upon completion of the 12-month follow-up for non-surgical participants.

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

1. september 2021

Primær færdiggørelse (Faktiske)

31. december 2024

Studieafslutning (Faktiske)

31. december 2024

Datoer for studieregistrering

Først indsendt

25. august 2021

Først indsendt, der opfyldte QC-kriterier

25. august 2021

Først opslået (Faktiske)

27. august 2021

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

14. august 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

12. august 2026

Sidst verificeret

1. august 2026

Mere information

Begreber relateret til denne undersøgelse

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner